HIV drug maraviroc may slow prostate cancer
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A drug used to treat HIV infection can slow the spread of prostate cancer, research has shown.
Early studies have shown the antiretroviral drug maraviroc can dramatically curb the spread of prostate cancer, that claims around 10,000 lives in the UK each year. Prostate cancer tumours most commonly travels to the bones, but treatment with maraviroc reduced the spread to the bones, brain and other organs by 60 per cent in mice.
Dr Richard Pestell, from Thomas Jefferson University in Philadelphia, said: “Because this work shows we can dramatically reduce metastasis in pre-clinical models, and because the drug is already... approved for HIV treatment, we may be able to test soon whether this drug can block metastasis in patients with prostate cancer.”
PA
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments